NYSE:BIOA (BIOA) (BIOA) Stock Price, News & Analysis → Controversial CEO explains new way to amass wealth (From Stansberry Research) (Ad) Free BIOA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$0.01▼$0.0350-Day Range N/A52-Week Range$0.01▼$2.88Volume15.51 million shsAverage Volume2.97 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (BIOA) alerts: Email Address Ad DTIIs Tesla going out of business?Goldman Sachs estimates that this new “Future Fuel” will unleash an $11.7 trillion wave of wealth over the coming decade. That’s 10 TIMES BIGGER than the electric vehicle market. Click here for the full story About (BIOA) Stock (NYSE:BIOA)BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.Read More Ad DTIIs Tesla going out of business?Goldman Sachs estimates that this new “Future Fuel” will unleash an $11.7 trillion wave of wealth over the coming decade. That’s 10 TIMES BIGGER than the electric vehicle market. Click here for the full story BIOA Stock News HeadlinesMay 3, 2024 | finance.yahoo.comThree Swedish Growth Companies With High Insider Ownership And Up To 53% Earnings GrowthApril 24, 2024 | finance.yahoo.comLeqembi® revenue totaled JPY 2.83 billion in the first quarter 2024May 7, 2024 | InvestorPlace (Ad)The 2024 crypto bull run has already started — don’t get left behindOne of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 21, 2024 | markets.businessinsider.comBioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's DiseaseApril 16, 2024 | finanznachrichten.deThe Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic ABApril 12, 2024 | morningstar.comCamurus AB CAMXApril 10, 2024 | finance.yahoo.comBioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq StockholmApril 6, 2024 | finance.yahoo.comB Jun 2024 50.000 callMay 7, 2024 | InvestorPlace (Ad)The 2024 crypto bull run has already started — don’t get left behindOne of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 6, 2024 | finance.yahoo.comB Sep 2024 40.000 putApril 6, 2024 | finance.yahoo.comB Sep 2024 30.000 putApril 1, 2024 | finance.yahoo.comSubmission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completedMarch 22, 2024 | finance.yahoo.comLecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasonsMarch 16, 2024 | finance.yahoo.comB Apr 2024 30.000 putMarch 16, 2024 | finance.yahoo.comB Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comB Apr 2024 45.000 callMarch 11, 2024 | finance.yahoo.comBioArctic: New data on lecanemab presented at the 2024 AD/PD™ congressMarch 7, 2024 | finance.yahoo.comBioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conferenceFebruary 29, 2024 | finanznachrichten.deBioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD congressFebruary 29, 2024 | finance.yahoo.comBioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congressFebruary 17, 2024 | morningstar.comBioiasis AD BIOAFebruary 6, 2024 | finanznachrichten.deBioArctic: Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023February 6, 2024 | finance.yahoo.comSales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023January 11, 2024 | finance.yahoo.comThe European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArcticJanuary 9, 2024 | finanznachrichten.deBioArctic: Leqembi® approved for the treatment of Alzheimer's disease in ChinaJanuary 9, 2024 | finance.yahoo.comLeqembi® approved for the treatment of Alzheimer's disease in ChinaDecember 13, 2023 | finance.yahoo.comLEQEMBI® to be launched in Japan for Alzheimer's disease on December 20See More Headlines Receive BIOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (BIOA) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2016Today5/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:BIOA CUSIPN/A CIK1534287 Webwww.bio-amber.com Phone+1-612-7474423FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesRaymond J. Land (Age 72)Chairman of the Board Richard P. EnoChief Financial Officer, DirectorMario SettinoChief Financial OfficerMichael A. Hartmann (Age 48)Executive Vice President James Millis (Age 59)Chief Technology Officer Robert FrostDirectorKurt W. Briner (Age 70)Independent Director Heinz Haller (Age 62)Independent Director Ellen B. Richstone (Age 65)Independent Director Kenneth W Wall (Age 66)Independent Director More Executives BIOA Stock Analysis - Frequently Asked Questions How were (BIOA)'s earnings last quarter? (BIOA) (NYSE:BIOA) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to analyst estimates of $2.37 million. What other stocks do shareholders of (BIOA) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (BIOA) investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), LadRx (CYTR), Intellipharmaceutics International (IPCIF), Biopharmx (BPMX), EyePoint Pharmaceuticals (EYPT), MoneyGram International (MGI), AbbVie (ABBV) and Aurinia Pharmaceuticals (AUPH). This page (NYSE:BIOA) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe asset beating inflation by 4xColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
